Skip to main content

Table 1 Demographic and laboratory data of stroke patients and control subjects.

From: Possible Anandamide and Palmitoylethanolamide involvement in human stroke

  Group A Group B p
Sex (M/F) 5/5 4/4 n.s.
Age yrs. (mean ± SD) 70 ± 13 70 ± 12 n.s.
NIHSS score (median ± SD; range) 22 ± 10; 3-29 - -
Fugl-Meyer Scale-arm score (median ± SD; range) 11.50 ± 9; 8-44 - -
CT ischemic area Volume (mL; mean ± SD) 76.10 ± 43.46 - -
Body Mass Index (mean ± SD) 25.20 ± 2.74 24.63 ± 2.39 n.s.
Cholesterol (mmol/L - mean ± SD) 11.69 ± 2.31 11.64 ± 2.04 n.s.
Triglycerides (mmol/L - mean ± SD) 6.97 ± 2.33 6.82 ± 1.00 n.s.
Blood Glucose (mmol/L - mean ± SD) 5.61 ± 0.71 5.77 ± 0.74 n.s.
AEA T0 (pmol/lipid mg - mean ± SD) 3.42 ± 2.71 1.81 ± 1.53 0.026
AEA T1 (pmol/lipid mg - mean ± SD) 2.87 ± 2.34 - n.s.
AEA T2 (pmol/lipid mg - mean ± SD) 3.11 ± 2.72 - n.s.
PEA TO (pmol/lipid mg - mean ± SD) 2.47 ± 0.96 2.05 ± 0.31 n.s.
PEA T1 (pmol/lipid mg - mean ± SD) 2.28 ± 1.01 - n.s.
PEA T2 (pmol/lipid mg - mean ± SD) 2.17 ± 0.67 - n.s.
2-AG T0 (pmol/lipid mg - mean ± SD) 3.42 ± 7.22 6.80 ± 9.50 n.s.
2-AG T1 (pmol/lipid mg - mean ± SD) 4.65 ± 4.98 - n.s.
2-AG T2 (pmol/lipid mg - mean ± SD) 3.29 ± 3.10 - n.s.
  1. Demographic, clinical, radiological data and endocannabinoid or PEA plasma levels in stroke patients (Group A, at T0, T1, and T2 time-points) and control subjects (Group B). p = p values (Mann-Whitney U test); n.s. = not significant.